Investigation of Cycloserine as a Smoking Cessation Treatment

Status Completed

Clinical Trial Summary

Psychosocial treatments for drug abuse benefit some patients (Rawson et al 2004), but there is an urgent need for new treatment approaches that can improve treatment outcomes. One new approach involves facilitation of extinction of conditioned responses through the use of d-cycloserine, a partial agonist at the NMDA glycine site. This approach has proved useful for the treatment of several anxiety disorders. For example, treatment with d-cycloserine enhanced the efficacy of behavioral treatments for acrophobia (Ressler et al 2004) and social phobia (Hofmann et al 2006) by enhancing extinction of conditioned fear responses. This suggests that d-cycloserine has potential to enhance the efficacy of behavioral treatments for drug dependence by enhancing extinction of conditioned responses to drug cues. In this Phase I Cutting-Edge Basic Research Awards (CEBRA) application we propose a proof-of-concept study to examine effects of treatment with d-cycloserine for facilitating extinction of craving provoked by exposure to cigarette smoking cues. The benefits of this treatment approach together with cognitive behavioral treatment for reducing cigarette smoking will then be determined. Smoking cues will be presented using an established virtual reality simulator(Bordnick et al 2004; Bordnick et al 2005a)

Clinical Trial Description

See brief summary ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Related Conditions & MeSH terms

Nicotine Addiction

Clinical Trial Details

NCT number	NCT01062932
Study type	Interventional
Source	Baylor College of Medicine
Contact
Status	Completed
Phase	Phase 1
Start date	May 2009
Completion date	September 2010

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02643914` - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings	N/A
Completed	`NCT02153749` - Effects of Brief Training on Craving Regulation	N/A
Recruiting	`NCT05530577` - Effects of Semaglutide on Nicotine Intake	Phase 2
Withdrawn	`NCT05440721` - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification	N/A
Completed	`NCT03694327` - Innovative Digital Therapeutic for Smoking Cessation	N/A
Completed	`NCT01944423` - Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine	Early Phase 1
Completed	`NCT01704573` - Nicotinic Receptor Levels After Stopping Smoking	N/A
Active, not recruiting	`NCT01015170` - STOP Study: Effectiveness of Zyban in a Clinical Population	Phase 4
Completed	`NCT03281629` - Circuitry-Guided Smoking Cessation in Schizophrenia	N/A
Recruiting	`NCT06291584` - Effects of Exercises on Functional Capacity	N/A
Withdrawn	`NCT06259630` - Nicotine Virtual Reality Conditioned Place Preference	Phase 4
Completed	`NCT02624284` - tDCS Effects on Resisting Smoking: Dose Ranging Study	N/A
Active, not recruiting	`NCT02837510` - Neural Mechanisms Associated With Risk of Smoking Relapse	N/A
Completed	`NCT02656745` - Clinical Trial of Smoking Cessation Mobile Phone Program	N/A
Completed	`NCT03069482` - Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness	Phase 1
Completed	`NCT02870218` - Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use	Phase 2
Terminated	`NCT01756053` - Effects of ABT-089 on Smoking Abstinence Symptoms and Reward	Phase 2
Completed	`NCT01252966` - Cognitive Training for Nicotine Dependence	N/A
Active, not recruiting	`NCT04946825` - Quit Smoking Study for People Who Use E-Cigarettes	Phase 2
Recruiting	`NCT05434429` - Mobile Health for Problematic Behaviors and Substance Use	N/A